In a recently published article, British authors summarize the current knowledge on the efficacy and safety of fenfluramine (FFA) in the treatment of Lennox-Gastaut syndrome (LGS, a developmental and epileptic encephalopathy). In addition to the reduction in seizure frequency demonstrated in clinical studies, they discuss the impact of fenfluramine on reducing the risk of sudden unexpected death in epilepsy (SUDEP), improving cognitive function in patients, and its safety concerning weight loss and heart disorders.
Don‘t have an account? Create new account
Authors: MUDr. Stanislav Voháňka, MBA. CSc.
Enter the email address that you registered with. We will send you instructions on how to set a new password.
